Base de dados : MEDLINE
Pesquisa : D02.145.074.722.744 [Categoria DeCS]
Referências encontradas : 522 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 53 ir para página                         

  1 / 522 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28679601
[Au] Autor:Sierra M; Martínez-Rodríguez I; Sánchez-Juan P; González-Aramburu I; Jiménez-Alonso M; Sánchez-Rodríguez A; Berciano J; Banzo I; Infante J
[Ad] Endereço:From the Neurology Service (M.S., P.S.-J., I.G.-A., A.S.-R., J.B., J.I.), University Hospital Marqués de Valdecilla and Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), IDIVAL, University of Cantabria (UC); and Nuclear Medicine Department (I.M.-R., M.J.-A., I.B
[Ti] Título:Prospective clinical and DaT-SPECT imaging in premotor G2019S-associated Parkinson disease.
[So] Source:Neurology;89(5):439-444, 2017 Aug 01.
[Is] ISSN:1526-632X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To assess the value of baseline clinical and imaging biomarkers in a cohort of asymptomatic G2019S carriers for predicting conversion to Parkinson disease (PD) at 4 years. METHODS: Thirty-two asymptomatic carriers of G2019S mutation underwent baseline and 4-year evaluation including clinical examination (Unified Parkinson's Disease Rating Scale, part III, olfaction University of Pennsylvania Smell Identification Test [UPSIT]) and dopamine transporter (DaT) SPECT ( I-ioflupane). Visual and semiquantitative analysis of images was performed. The specific striatal binding ratio was calculated (striatal region of interest [ROI] - occipital ROI/occipital ROI). RESULTS: Three carriers, asymptomatic at baseline, had converted to PD at 4-year evaluation. Twenty-three participants were fully evaluated. PD converters had lower striatal DaT binding at baseline than nonconverters ( = 0.002). A baseline scan with a ratio of bilateral striatal uptake below 1 predicted conversion to PD within the 4-year period with high sensitivity and specificity (area under the curve 1; = 0.006). The slope of DaT binding decline between the 2 scans was similar in PD converters and nonconverters. Age-adjusted UPSIT score at baseline and at 4 years was similar in both groups. CONCLUSIONS: Semiquantitative DaT-SPECT could be used to predict early conversion to PD in asymptomatic carriers of the G2019S mutation. Rate of conversion to PD at 4 years in this cohort aged ∼64 years was 12%. The slope of DaT binding decline on DaT-SPECT imaging seems to be similar across different stages of the premotor period.
[Mh] Termos MeSH primário: Corpo Estriado/diagnóstico por imagem
Proteínas da Membrana Plasmática de Transporte de Dopamina/metabolismo
Serina-Treonina Proteína Quinase-2 com Repetições Ricas em Leucina/genética
Doença de Parkinson/diagnóstico por imagem
Doença de Parkinson/genética
Tomografia Computadorizada de Emissão de Fóton Único
[Mh] Termos MeSH secundário: Fatores Etários
Mapeamento Encefálico
Corpo Estriado/metabolismo
Progressão da Doença
Família
Feminino
Heterozigoto
Seres Humanos
Estudos Longitudinais
Masculino
Meia-Idade
Mutação
Nortropanos
Doença de Parkinson/metabolismo
Sintomas Prodrômicos
Estudos Prospectivos
Compostos Radiofarmacêuticos
Índice de Gravidade de Doença
Olfato
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dopamine Plasma Membrane Transport Proteins); 0 (Nortropanes); 0 (Radiopharmaceuticals); EC 2.7.11.1 (LRRK2 protein, human); EC 2.7.11.1 (Leucine-Rich Repeat Serine-Threonine Protein Kinase-2); VF232WE742 (ioflupane)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170707
[St] Status:MEDLINE
[do] DOI:10.1212/WNL.0000000000004185


  2 / 522 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28368892
[Au] Autor:Goethals L; Bourgeois S; De Brucker Y; Everaert H; De Geeter FW
[Ad] Endereço:From the Departments of *Nuclear Medicine, and †Radiology, Universitair Ziekenhuis Brussel, Brussels; and ‡Department of Nuclear Medicine, Algemeen Ziekenhuis Sint-Jan Brugge-Oostende, Brugge, Belgium.
[Ti] Título:Unilaterally Decreased Striatal Dopamine Transporter Caused by Venous Anomaly.
[So] Source:Clin Nucl Med;42(6):e306-e307, 2017 Jun.
[Is] ISSN:1536-0229
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We describe a finding of unilaterally decreased binding of I-ioflupane in the basal ganglia in a 78-year-old woman that could be attributed to an underlying developmental venous anomaly.
[Mh] Termos MeSH primário: Veias Cerebrais
Proteínas da Membrana Plasmática de Transporte de Dopamina/metabolismo
Neostriado/metabolismo
Doenças Vasculares/metabolismo
[Mh] Termos MeSH secundário: Idoso
Gânglios da Base/metabolismo
Seres Humanos
Masculino
Nortropanos/metabolismo
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dopamine Plasma Membrane Transport Proteins); 0 (Nortropanes); VF232WE742 (ioflupane)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170404
[St] Status:MEDLINE
[do] DOI:10.1097/RLU.0000000000001657


  3 / 522 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28120444
[Au] Autor:Orgen S; Deliktas H; Sahin H; Gedik A; Nergis Y
[Ad] Endereço:Department of Urology, Batman State Hospital, Batman, Turkey.
[Ti] Título:Histopathologic and Urodynamic Effects of the Anticholinergic Drugs Oxybutynin, Tolterodine, and Trospium on the Bladder.
[So] Source:Low Urin Tract Symptoms;9(1):52-56, 2017 Jan.
[Is] ISSN:1757-5672
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: This study aimed to evaluate the effects of intravesical instillation of the anticholinergic drugs oxybutynin, tolterodine, and trospium on bladder capacity and histopathological changes in the bladder mucosa. METHODS: The study included 20 male New Zealand white rabbits that were randomly allocated to four groups of five. In the oxybutynin, tolterodine, and trospium groups, the drugs used were 1 mg/kg of crushed tablet mixed with 5 mL of saline, instilled intravesically once per day for 4 weeks. The control group was administered only 5 mL of saline once per day for 4 weeks. Urodynamic measurement of the bladder was made before and after treatment. At the end of the treatment the animals were killed and the bladders were evaluated histopathologically. RESULTS: There were no significant differences between pre- and post-treatment bladder capacity in any of the groups (P > 0.05). Histopathological evaluation showed that the mucosal epithelium was intact and there was minor inflammation in the control group and oxybutynin group (P > 0.05), whereas there was destruction of the mucosal epithelium and findings of diffuse inflammation in the tolterodine (P = 0.014) and trospium (P = 0.014) groups. CONCLUSION: Intravesical oxybutynin treatment was observed to be safe; however, a single daily dose of oxybutynin may not be sufficient to increase bladder capacity. Intravesical use of trospium and tolterodine at high doses caused epithelial destruction and diffuse inflammation in the bladder mucosa. The irritation associated with epithelial destruction and inflammation prevented an increase in bladder capacity.
[Mh] Termos MeSH primário: Benzilatos/farmacologia
Ácidos Mandélicos/farmacologia
Antagonistas Muscarínicos/farmacologia
Nortropanos/farmacologia
Tartarato de Tolterodina/farmacologia
Bexiga Urinária/efeitos dos fármacos
Agentes Urológicos/farmacologia
[Mh] Termos MeSH secundário: Animais
Masculino
Coelhos
Distribuição Aleatória
Urotélio/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Benzilates); 0 (Mandelic Acids); 0 (Muscarinic Antagonists); 0 (Nortropanes); 0 (Urological Agents); 1E6682427E (trospium chloride); 5T619TQR3R (Tolterodine Tartrate); K9P6MC7092 (oxybutynin)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170606
[Lr] Data última revisão:
170606
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170126
[St] Status:MEDLINE
[do] DOI:10.1111/luts.12096


  4 / 522 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28074677
[Au] Autor:Kosilov K; Loparev S; Kuzina I; Shakirova O; Zhuravskaya N; Lobodenko A
[Ad] Endereço:a Department of Social Sciences , Far Eastern Federal University , Vladivostok , Russia.
[Ti] Título:The effective tool for self-assessment of adherence to treatment in patients with benign prostatic obstruction and overactive bladder symptoms.
[So] Source:Aging Male;20(1):39-44, 2017 Mar.
[Is] ISSN:1473-0790
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Study of validity of the Medication Adherence Self-Report Inventory (MASRI) for use in clinical practice to treat patients with benign prostatic obstruction (BPO) accompanied with overactive bladder (OAB) symptoms. METHODS: During 12 weeks of the randomized study, 452 patients with BPO and OAB symptoms (mean age of 61.3 (12.7)) were studied for adherence to the treatment with Tamsulosin, Solifenacin and Trospium using the MASRI. External monitoring instruments included the Brief Medication Questionnaire (BMQ) and the visual remaining pill count. The state of the prostate gland and the lower urinary tract was monitored using questionnaires I-PSS, OAB Awareness Tool, uroflowmetry and voiding diaries. RESULT: Correlation between the percentage of men non-adherent to treatment (MASRI) and the percentage of patients having a belief barrier on the screen of the BMQ was r = 0.89, p ≤0.05, r = 0.92, p ≤0.01, r = 0.85, p ≤0.05, a number of missed doses on the Regimen Screen of the BMQ was r = 0.79; p ≤0.05; r = 0.81; p ≤0.05; r = 0.75, p ≤0.05, a number of non-adherent patients according to the BMQ was r = 0.83 (p ≤0.05), r = 0.88 (p ≤0.05), r = 0.79, p ≤0.05, the results of the pill count were r = 0.65-0.76; p ≤0.05-0.01. These data confirm high validity of the MASRI. CONCLUSION: The MASRI is a valid tool for rapid assessment of adherence to treatment of patients with BPO and OAB receiving Tamsulosin and antimuscarinic drugs and may be recommended for use in clinical practice.
[Mh] Termos MeSH primário: Adesão à Medicação
Hiperplasia Prostática/tratamento farmacológico
Autoavaliação
Bexiga Urinária Hiperativa/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Benzilatos/uso terapêutico
Autoavaliação Diagnóstica
Quimioterapia Combinada
Seres Humanos
Masculino
Meia-Idade
Antagonistas Muscarínicos/uso terapêutico
Nortropanos/uso terapêutico
Hiperplasia Prostática/complicações
Succinato de Solifenacina/uso terapêutico
Sulfonamidas/uso terapêutico
Inquéritos e Questionários
Bexiga Urinária Hiperativa/complicações
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Benzilates); 0 (Muscarinic Antagonists); 0 (Nortropanes); 0 (Sulfonamides); 1E6682427E (trospium chloride); G3P28OML5I (tamsulosin); KKA5DLD701 (Solifenacin Succinate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170112
[St] Status:MEDLINE
[do] DOI:10.1080/13685538.2016.1247435


  5 / 522 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27813429
[Au] Autor:Isaacson SH; Fisher S; Gupta F; Hermanowicz N; Kremens DE; Lew MF; Marek K; Pahwa R; Russell DS; Seibyl J
[Ad] Endereço:a Parkinson's Disease and Movement Disorders Center of Boca Raton , FL , USA.
[Ti] Título:Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective.
[So] Source:Expert Rev Neurother;17(3):219-225, 2017 Mar.
[Is] ISSN:1744-8360
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Single photon emission computed tomography (SPECT) with Ioflupane I123 injection (DaTscan™) was approved by the Food and Drug Administration in 2011 for striatal dopamine transporter visualization to assist in the evaluation of adult patients with suspected parkinsonian syndromes. While brain SPECT imaging using DaTscan is a covered service under Medicare policy, there is a lack of consensus on its role in routine clinical practice in the US. Areas covered: To address this issue, an expert group of US-based movement disorders neurologists convened to discuss the clinical utility of DaTscan in movement disorders practices within the US. The group identified and discussed routine clinical scenarios where imaging with DaTscan can provide useful information that may impact management and/or clarify clinical diagnoses. This paper summarizes a consensus reached by the expert group at this meeting. Expert commentary: The major utility of DaTscan imaging is the assistance it provides in distinguishing between nigrostriatal dopaminergic degeneration and non-nigrostriatal degeneration in patients displaying equivocal signs and symptoms of parkinsonism.
[Mh] Termos MeSH primário: Nortropanos
Transtornos Parkinsonianos/diagnóstico por imagem
Tomografia Computadorizada de Emissão de Fóton Único/métodos
[Mh] Termos MeSH secundário: Diagnóstico Diferencial
Proteínas da Membrana Plasmática de Transporte de Dopamina
Seres Humanos
Doença de Parkinson/diagnóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Dopamine Plasma Membrane Transport Proteins); 0 (Nortropanes); VF232WE742 (ioflupane)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161105
[St] Status:MEDLINE
[do] DOI:10.1080/14737175.2017.1256205


  6 / 522 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27614874
[Au] Autor:Graebner AK; Tarsy D; Shih LC; Vanderhorst V; Kulkarni O; Kaplan S; Simon DK
[Ad] Endereço:Parkinson's Disease and Movement Disorders Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass., USA.
[Ti] Título:Clinical Impact of 123I-Ioflupane SPECT (DaTscan) in a Movement Disorder Center.
[So] Source:Neurodegener Dis;17(1):38-43, 2017.
[Is] ISSN:1660-2862
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIMS: The clinical diagnosis of degenerative forms of parkinsonism is imperfect, with past studies reporting a high rate of misdiagnosis by neurologists and movement disorder specialists, particularly early in the disease course. 123I-ioflupane SPECT (DaTscan) is a diagnostic neuroimaging tool used to distinguish essential tremor from tremor due to degenerative parkinsonisms. The present study expands upon prior studies of the clinical impact of DaTscan imaging in movement disorder centers by assessing quantitative estimates of diagnostic certainty, the impact on subsequent clinical decisions, and the degree to which the asymmetry in the results corresponds to laterality by clinical history and examination. METHODS: In a prospective, observational study of the impact of DaTscan imaging in a movement disorder center over the course of 18 months, 4 specialists completed a questionnaire at the time they ordered imaging and again within 1 month after imaging. RESULTS: Twenty-seven patients underwent DaTscan imaging; the result was normal in 4 cases (14.8%), abnormal in 22 cases (81.4%), and equivocal in 1 case (3.7%). In all cases of a normal result, the post-scan-predicted chance of degenerative parkinsonism decreased compared to the pre-scan prediction (p < 0.05), and in all cases of abnormal scan, the post-scan chance of degenerative parkinsonism increased or remained high (p < 0.0001). Clinical impacts were observed following imaging in a total of 24 patients (88.9%), including changes in medications for 18 patients and psychological impacts for 11 patients. Asymmetric clinical symptoms were corroborated based on the expected asymmetry of dopamine uptake deficits in 57.1% of the cases, were not present in 23.8%, and were opposite of expectations in 19.0% of the scans. CONCLUSION: DaTscan imaging results have an impact on physician's confidence in the diagnosis of parkinsonism and may also have a psychological impact on patients. DaTscan imaging may be a useful adjunct to clinical history and examination in selected patients.
[Mh] Termos MeSH primário: Encéfalo/diagnóstico por imagem
Transtornos dos Movimentos/diagnóstico por imagem
Nortropanos
Transtornos Parkinsonianos/diagnóstico por imagem
Compostos Radiofarmacêuticos
Tomografia Computadorizada de Emissão de Fóton Único
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Tomada de Decisão Clínica
Diagnóstico Diferencial
Feminino
Seres Humanos
Masculino
Meia-Idade
Transtornos dos Movimentos/terapia
Neuroimagem
Transtornos Parkinsonianos/terapia
Centros de Atenção Terciária
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Nortropanes); 0 (Radiopharmaceuticals); VF232WE742 (ioflupane)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160912
[St] Status:MEDLINE


  7 / 522 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27572945
[Au] Autor:Mille E; Levin J; Brendel M; Zach C; Barthel H; Sabri O; Bötzel K; Bartenstein P; Danek A; Rominger A
[Ad] Endereço:Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany.
[Ti] Título:Cerebral Glucose Metabolism and Dopaminergic Function in Patients with Corticobasal Syndrome.
[So] Source:J Neuroimaging;27(2):255-261, 2017 03.
[Is] ISSN:1552-6569
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND PURPOSE: The corticobasal syndrome (CBS) is a clinical diagnosis that comprises a group of rare neurodegenerative diseases manifesting in movement disorder and cognitive impairment. While diagnosis is based upon clinical criteria, there have been a number of molecular imaging studies, albeit in rather small cohorts. Therefore, we investigated the pattern of cerebral glucose metabolism, as well as dopamine transporter (DAT) availability in a large and clinically well-defined cohort. METHODS: Thirty-four patients fulfilling either the Armstrong or the Boeve criteria were assessed with [ F]-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) and/or [ I]-Ioflupane single-photon-emission-computed tomography (SPECT) for DAT availability. A small subset of patients had also undergone D receptor imaging. Imaging data were analyzed using both statistical parametric mapping and a volume-of-interest-based approach relative to data from healthy controls. RESULTS: Significant reductions of the cortical glucose metabolism were observed in the central region and the adjacent frontal and parietal association areas contralateral to the side with predominant motor symptoms. Reductions were also evident in the basal ganglia, notably in the putamen contralateral to the clinically affected side, and in the bilateral thalamus. DAT availability was reduced bilaterally, most distinctly on the side contralateral to the main motor symptoms. CONCLUSIONS: We replicated and refined earlier findings of impaired glucose metabolism and nigrostriatal degeneration in CBS, highlighting asymmetric cortical and subcortical hypometabolism, symmetrically reduced metabolism in the thalamus, and only a slightly asymmetric reduction in DAT, while D receptors seem to be mainly preserved. These results provide systematic evidence for the usefulness of FDG PET and dopaminergic SPECT imaging to characterize CBS.
[Mh] Termos MeSH primário: Encéfalo/metabolismo
Proteínas da Membrana Plasmática de Transporte de Dopamina/metabolismo
Glucose/metabolismo
Doenças Neurodegenerativas/metabolismo
Receptores Dopaminérgicos/metabolismo
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Dopamina/metabolismo
Feminino
Fluordesoxiglucose F18
Seres Humanos
Masculino
Meia-Idade
Nortropanos
Tomografia por Emissão de Pósitrons
Compostos Radiofarmacêuticos
Síndrome
Tomografia Computadorizada de Emissão de Fóton Único
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dopamine Plasma Membrane Transport Proteins); 0 (Nortropanes); 0 (Radiopharmaceuticals); 0 (Receptors, Dopamine); 0Z5B2CJX4D (Fluorodeoxyglucose F18); IY9XDZ35W2 (Glucose); VF232WE742 (ioflupane); VTD58H1Z2X (Dopamine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160831
[St] Status:MEDLINE
[do] DOI:10.1111/jon.12391


  8 / 522 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28247723
[Au] Autor:Krivoborodov GG; Tur EI; Efremov NS; Shkolnikov ME
[Ad] Endereço:Department of Faculty Surgery, Urology of the Medical Faculty RNSMU n.a. N.I. Pirogov, RCRC of Gerontology.
[Ti] Título:[High doses of trospium chloride in patients with idiopathic overactive bladder. Data of large-scale, multicenter observational program Resource].
[So] Source:Urologiia;(4):29-34, 2016 Aug.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:PURPOSE: Evaluation of the efficacy and safety of different doses of trospium chloride in patients with idiopathic overactive bladder. MATERIALS AND METHODS: Large-scale observational program "Resource" included 669 patients with idiopathic OAB - 359 women and 310 men. At the first visit, all patients were assigned to use of trospium chloride at a standard dose of 45 mg per day. The results of treatment were evaluated during follow-up visits at 3, 6, 9 and 12 weeks. Depending on the results of examination, the dose was reduced in the presence of adverse events and increased in case of insufficient treatment effects. RESULTS: After 12 weeks, 102 patients have been receiving the drug at a dose of 30 mg/day, 241 - at a dose of 45 mg/day, 257 - at a dose of 60 mg/day, and 22 - at a dose of 75 mg/day. CONCLUSIONS: Individual approach to the selection of doses of trospium chloride in patients with idiopathic OAB can be quite effective and safe measure to achieve optimal clinical outcome with a good safety profile.
[Mh] Termos MeSH primário: Benzilatos/uso terapêutico
Antagonistas Colinérgicos/uso terapêutico
Nortropanos/uso terapêutico
Bexiga Urinária Hiperativa/tratamento farmacológico
[Mh] Termos MeSH secundário: Benzilatos/administração & dosagem
Benzilatos/efeitos adversos
Antagonistas Colinérgicos/administração & dosagem
Antagonistas Colinérgicos/efeitos adversos
Relação Dose-Resposta a Droga
Feminino
Seres Humanos
Masculino
Meia-Idade
Nortropanos/administração & dosagem
Nortropanos/efeitos adversos
Qualidade de Vida
Bexiga Urinária Hiperativa/psicologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Benzilates); 0 (Cholinergic Antagonists); 0 (Nortropanes); 1E6682427E (trospium chloride)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171026
[Lr] Data última revisão:
171026
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170302
[St] Status:MEDLINE


  9 / 522 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27995072
[Au] Autor:Rahmim A; Salimpour Y; Jain S; Blinder SA; Klyuzhin IS; Smith GS; Mari Z; Sossi V
[Ad] Endereço:Department of Radiology, Johns Hopkins University, Baltimore, MD, United States; Department of Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, United States.
[Ti] Título:Application of texture analysis to DAT SPECT imaging: Relationship to clinical assessments.
[So] Source:Neuroimage Clin;12:e1-e9, 2016.
[Is] ISSN:2213-1582
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Dopamine transporter (DAT) SPECT imaging is increasingly utilized for diagnostic purposes in suspected Parkinsonian syndromes. We performed a cross-sectional study to investigate whether assessment of texture in DAT SPECT radiotracer uptake enables enhanced correlations with severity of motor and cognitive symptoms in Parkinson's disease (PD), with the long-term goal of enabling clinical utility of DAT SPECT imaging, beyond standard diagnostic tasks, to tracking of progression in PD. Quantitative analysis in routine DAT SPECT imaging, if performed at all, has been restricted to assessment of mean regional uptake. We applied a framework wherein textural features were extracted from the images. Notably, the framework did not require registration to a common template, and worked in the subject-native space. Image analysis included registration of SPECT images onto corresponding MRI images, automatic region-of-interest (ROI) extraction on the MRI images, followed by computation of Haralick texture features. We analyzed 141 subjects from the Parkinson's Progressive Marker Initiative (PPMI) database, including 85 PD and 56 healthy controls (HC) (baseline scans with accompanying 3 T MRI images). We performed univariate and multivariate regression analyses between the quantitative metrics and different clinical measures, namely (i) the UPDRS (part III - motor) score, disease duration as measured from (ii) time of diagnosis (DD-diag.) and (iii) time of appearance of symptoms (DD-sympt.), as well as (iv) the Montreal Cognitive Assessment (MoCA) score. For conventional mean uptake analysis in the putamen, we showed significant correlations with clinical measures only when both HC and PD were included (Pearson correlation  = - 0.74, p-value < 0.001). However, this was not significant when applied to PD subjects only ( = - 0.19, p-value = 0.084), and no such correlations were observed in the caudate. By contrast, for the PD subjects, significant correlations were observed in the caudate when including texture metrics, with (i) UPDRS (p-values < 0.01), (ii) DD-diag. (p-values < 0.001), (iii) DD-sympt (p-values < 0.05), and (iv) MoCA (p-values < 0.01), while no correlations were observed for conventional analysis (p-values = 0.94, 0.34, 0.88 and 0.96, respectively). Our results demonstrated the ability to capture valuable information using advanced texture metrics from striatal DAT SPECT, enabling significant correlations of striatal DAT binding with clinical, motor and cognitive outcomes, and suggesting that textural features hold potential as biomarkers of PD severity and progression.
[Mh] Termos MeSH primário: Proteínas da Membrana Plasmática de Transporte de Dopamina/metabolismo
Doença de Parkinson/diagnóstico por imagem
Tomografia Computadorizada de Emissão de Fóton Único
[Mh] Termos MeSH secundário: Idoso
Análise de Variância
Estudos Transversais
Feminino
Seres Humanos
Imagem por Ressonância Magnética
Masculino
Meia-Idade
Nortropanos/farmacocinética
Escalas de Graduação Psiquiátrica
Compostos Radiofarmacêuticos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dopamine Plasma Membrane Transport Proteins); 0 (Nortropanes); 0 (Radiopharmaceuticals); VF232WE742 (ioflupane)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161221
[St] Status:MEDLINE


  10 / 522 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27765726
[Au] Autor:Tadken T; Weiss M; Modess C; Wegner D; Roustom T; Neumeister C; Schwantes U; Schulz HU; Weitschies W; Siegmund W
[Ad] Endereço:Department of Clinical Pharmacology, Center of Drug Absorption and Transport, University Medicine of Greifswald, Greifswald, Germany.
[Ti] Título:Trospium chloride is absorbed from two intestinal "absorption windows" with different permeability in healthy subjects.
[So] Source:Int J Pharm;515(1-2):367-373, 2016 Dec 30.
[Is] ISSN:1873-3476
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Intestinal P-glycoprotein is regio-selectively expressed and is a high affinity, low capacity efflux carrier for the cationic, poorly permeable trospium. Organic cation transporter 1 (OCT1) provides lower affinity but higher capacity for trospium uptake. To evaluate regional intestinal permeability, absorption profiles after gastric infusion of trospium chloride (30mg/250ml=[I] ) for 6h and after swallowing 30mg immediate-release tablets in fasted and fed healthy subjects, were evaluated using an inverse Gaussian density function to model input rate and mean absorption time (MAT). Trospium chloride was slowly absorbed (MAT ∼10h) after gastric infusion involving two processes with different input rates, peaking at about 3h and 7h. Input rates and MAT were influenced by dosage form and meal. In conclusion, trospium is absorbed from two "windows" located in the jejunum and cecum/ascending colon, whose uptake capacity might result from local abundance and functional interplay of P-glycoprotein and OCT1.
[Mh] Termos MeSH primário: Benzilatos/metabolismo
Ceco/metabolismo
Colo Ascendente/metabolismo
Absorção Intestinal/fisiologia
Jejuno/metabolismo
Nortropanos/metabolismo
[Mh] Termos MeSH secundário: Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo
Adulto
Feminino
Voluntários Saudáveis
Seres Humanos
Masculino
Transportador 1 de Cátions Orgânicos/metabolismo
Permeabilidade
Comprimidos/metabolismo
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ATP-Binding Cassette, Sub-Family B, Member 1); 0 (Benzilates); 0 (Nortropanes); 0 (Organic Cation Transporter 1); 0 (Tablets); 1E6682427E (trospium chloride)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161106
[St] Status:MEDLINE



página 1 de 53 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde